Natalizumab
| Use attributes for filter ! | |
| Target | alpha-4 integrin |
|---|---|
| License data | EU |
| EMA | |
| US | |
| FDA | |
| Elimination half-life | 11 ± 4 days |
| Source | Humanized (from mouse) |
| ATC code | L04AA23 (WHO) |
| Music groups | Ocrelizumab |
| Fingolimod | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951382 |
About Natalizumab
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days.